California-Based Welltory Raises $2M in Seed Funding

Welltory, a Redwood City, California-based consumer health app provider, has raised $2 million in debt financing from Braavo Capital.

The company plans to use the funding to support growth and recruitment for Welltory Care, a service that provides specialized support for people living with chronic health conditions.

Welltory Care focuses on conditions such as post-exertional malaise (PEM), migraine, long COVID, chronic fatigue, and irritable bowel syndrome.

What is Welltory?

Welltory is a consumer health platform that helps people understand their physiology, stress, recovery, and overall wellbeing using wearable data and heart rate variability (HRV) analysis.

Read More:California-Based Voltus Secures $225M in Series D Funding

The company also uses digital phenotyping, which combines wearable data with information users report about their daily experiences. This helps identify people with similar physiological patterns and health-related challenges.

Through Welltory Care, the company brings together people with similar conditions and daily limitations. The service combines peer support and shared strategies with personal data, research, and medical expertise.

How Much Funding Has Welltory Raised?

Welltory has secured $2 million in debt financing from Braavo Capital.

The announcement does not disclose the company's total funding raised to date. However, Braavo has provided Welltory with several million dollars in growth financing over the course of their long-term partnership.

Who Invested in Welltory’s Seed Funding?

Braavo Capital provided the latest $2 million in debt financing.

The announcement describes the financing as part of an ongoing relationship between the two companies. It does not identify any other investors in this round.

Why the Funding Matters

Welltory will use the financing primarily to support growth and recruitment for Welltory Care.

The funding will help the company expand specialized support groups and services for people managing chronic conditions. Welltory funds its research and product development through its own resources, while Braavo's financing will focus mainly on growing the Care service.

Who founded Welltory?

Welltory was founded in 2016 by Jane Smorodnikova. The company is based in Redwood City, California.

It develops consumer health technology that uses wearable data and HRV analysis to help users better understand their physiological patterns and wellbeing.

"Most health products are built for the average user, but chronic conditions aren't average experiences," said Veranika Zdanovich, CCO of Welltory. "With 18 million users, we can bring together people whose physiology and daily limitations are unusually similar, then build research and tools around what that specific group actually needs."

"Welltory has been a long-term partner of Braavo and it's incredibly rewarding to see the company continue to grow while staying true to its mission," said Mark Loranger, CEO of Braavo Capital. "We're proud to have played a role in that journey and to support work that can improve the health and wellbeing of millions of people."

Market and Business Growth

Three months before the funding announcement, Welltory launched its first Energy Lab group for people experiencing post-exertional malaise. The group started with 100 participants.

Following strong engagement, the company plans to expand the group to 500 participants. Clinical outcomes are also being collected through an Institutional Review Board (IRB)-approved study.

Welltory is using its digital phenotyping technology to identify people with similar physiological profiles and develop more specialized support services. The announcement does not disclose revenue or overall user numbers.

What Happens Next?

Welltory plans to expand Welltory Care by recruiting more people and growing its specialized support groups for chronic conditions.

The company also plans to expand its first Energy Lab group from 100 to 500 participants while collecting clinical outcomes through its IRB-approved study.

Read More:Medical Microinstruments Raises $125M in Series D Funding